A new lung cancer drug kept patients alive 18.5 months against chemotherapy’s 10

Patients on an experimental drug called gotistobart lived a median of 18.5 months after starting treatment for advanced squamous non-small cell lung cancer, compared with 10.0 months for patients given the standard chemotherapy drug docetaxel. BioNTech and OncoC4, the companies co-developing the antibody, presented the updated results on September 14 in Seoul at the International Association for the Study of Lung Cancer’s 2026 World Conference on Lung Cancer.

The data come from stage 1 of a two-part, 87-patient trial called PRESERVE-003, run in people whose squamous NSCLC had already progressed after immunotherapy and platinum-based chemotherapy — a group with few remaining options and a prognosis usually measured in months.

A CTLA-4 antibody built to avoid its own side effects

Gotistobart, also known as BNT316 or ONC-392, targets CTLA-4, a checkpoint protein that dampens the immune system’s attack on tumors. Older CTLA-4 drugs like ipilimumab work but often cause severe autoimmune-style side effects because they suppress the checkpoint everywhere in the body, not just inside the tumor. Gotistobart is engineered differently: it is a pH-sensitive antibody that unbinds from CTLA-4 once the drug-receptor complex is pulled inside a cell, letting the receptor recycle back to the surface in normal tissue while still depleting the regulatory T cells that protect a tumor from immune attack, according to OncoC4’s description of the mechanism. Squamous NSCLC, which makes up roughly a quarter to a third of all lung cancer cases and is the subtype most common among smokers, has historically had fewer targeted treatment options than the adenocarcinoma form of the disease, according to Targeted Oncology’s coverage of the drug’s development.

Yang Liu, co-founder and chief scientific officer of OncoC4, has said the mechanism’s promise extends beyond lung cancer. “The mechanism of action of gotistobart has the potential for clinical development of the drug beyond lung cancers for other indications with unmet medical needs, either as monotherapy or in combination with other therapeutic modalities,” Liu said.

The September update nearly doubled the earlier survival numbers

At the July 17, 2026 data cutoff, with a median follow-up of 25.4 months, 87 patients with metastatic squamous NSCLC had been randomized to either gotistobart monotherapy (45 patients) or docetaxel (42 patients) in the second-line-or-later setting, according to BioNTech and OncoC4’s joint announcement. Median overall survival reached 18.5 months on gotistobart against 10.0 months on docetaxel, a difference the companies calculated as a hazard ratio of 0.56, meaning roughly a 44% lower risk of death on the experimental drug (nominal p-value 0.0295). Grade 3 or higher treatment-related adverse events occurred in 44.4% of the gotistobart group and 48.8% of the docetaxel group, putting the safety profiles close to even even as the survival curves diverged.

That 18.5-versus-10.0 figure is itself a jump from what the same trial arm showed a year earlier. In a 2025 readout with only 14.5 months of median follow-up, median survival in the gotistobart arm had not yet been reached at all, versus the same 10.0-month docetaxel benchmark, a result that had already drawn attention as an unusually early separation between the two curves.

An oncologist who treats these patients calls the gap unprecedented

Rama Balaraman, principal investigator on the trial and a medical oncologist at Ocala Oncology Center in Florida, described the scale of the problem gotistobart is aimed at. “Current survival expectations with established therapies remain less than a year, and despite numerous development efforts, chemotherapy has remained the standard of care in this setting for more than a decade,” Balaraman said. “The magnitude of the survival benefit observed with gotistobart as a chemotherapy-free treatment approach in the PRESERVE-003 clinical trial is highly encouraging. If confirmed in the pivotal portion of the Phase 3 trial, these findings could transform the standard of care in a setting where new therapies are urgently needed.”

Özlem Türeci, BioNTech’s co-founder and chief medical officer, tied the result to a broader push to re-activate immune systems that have stopped responding to treatment. “In second- and later lines of treatment, the clinical relevance of novel therapeutic options depends on the ability to re-engage a suppressed or exhausted anti-tumor immune response and overcome acquired resistance,” Türeci said, calling the update evidence of “gotistobart’s unique mode of action” in a population that has run out of easier options.

Pan Zheng, OncoC4’s co-founder and chief medical officer, framed the data as validation of years spent trying to separate a CTLA-4 drug’s tumor-killing effect from its toxicity. “The data support the differentiated mechanism of action of gotistobart as a tumor microenvironment-selective Treg modulator and reinforce our confidence in the therapeutic potential of this distinct CTLA-4-targeting approach to meaningfully shift the treatment landscape in this indication,” Zheng said.

A larger trial will decide whether the result holds

Stage 1 of PRESERVE-003 was designed mainly to confirm dosing, not to serve as the trial that wins approval. That pivotal decision now rests with stage 2 of the trial, registered with the National Institutes of Health as NCT05671510, which is enrolling patients with squamous NSCLC exclusively and is active at more than 160 sites worldwide, testing gotistobart against docetaxel head to head in a larger population. The trial’s design and stage 1 findings were also published in a peer-reviewed Nature Medicine paper documenting the randomized comparison, giving outside researchers a way to scrutinize the numbers beyond the conference presentation and company statements.

Until stage 2 reads out, gotistobart remains unapproved and unavailable outside clinical trials, and the FDA has so far granted it only fast track and orphan drug designations rather than any form of marketing clearance. Those designations speed up the regulatory review process and grant certain financial incentives, but they are not endorsements of the drug’s eventual safety or effectiveness. The gap between a 25.4-month interim readout and the pivotal data needed for approval is exactly the stretch where promising early cancer drugs most often fail to hold their advantage once tested in larger, more diverse patient groups.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview